- Home
- TERN
as 11-15-2024 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 586.0M | IPO Year: | 2021 |
| Target Price: | $16.42 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.59 - $11.40 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lu Hongbo | TERN | Director | Sep 12 '24 | Buy | $10.50 | 476,190 | $4,999,995.00 | 190,476 | |
| Vignola Mark J. | TERN | Chief Financial Officer | Sep 10 '24 | Sell | $11.00 | 10,000 | $110,000.00 | 91,940 | |
| Quigley Jill M. | TERN | Director | Sep 9 '24 | Sell | $10.00 | 17,235 | $172,350.00 | 15,000 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
GlobeNewswire
5 days ago
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
11 days ago
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
MT Newswires
17 days ago
Oppenheimer Initiates Terns Pharmaceuticals at Outperform With $17 Price Target
GlobeNewswire
a month ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
MT Newswires
2 months ago
Mizuho Raises Price Target on Terns Pharmaceuticals to $14 From $10, Keeps Outperform Rating
TipRanks
2 months ago
Insiders Snap Up These 2 ‘Strong Buy’ Stocks
Motley Fool
2 months ago
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.